Biogen Presents Positive Phase 2 Cutaneous Lupus Erythematosus (CLE) Data at European E-Congress of Rheumatology (EULAR) 2020
04 juin 2020 07h30 HE
|
Biogen Inc.
Full analysis of the CLE part of the LILAC study reinforces positive top-line results; participants who received BIIB059 (anti-BDCA2) demonstrated statistically significant reduction of disease...
Biogen Reports Top-Line Results from Phase 2 Study in Progressive Supranuclear Palsy
13 déc. 2019 07h30 HE
|
Biogen Inc.
CAMBRIDGE, Mass., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Today, Biogen Inc. (Nasdaq: BIIB) announced topline results from the Phase 2 PASSPORT study of gosuranemab (BIIB092) for progressive supranuclear...
Biogen Announces Positive Phase 2 Study Results for Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE)
03 déc. 2019 07h30 HE
|
Biogen Inc.
The Phase 2 LILAC study met its primary endpoints, demonstrating statistically significant reduction of disease activity in patients with CLE and SLE who received BIIB059 compared to placeboPositive...
UPMC Health Plan and Biogen Announce Groundbreaking Value-Based Agreement for Multiple Sclerosis Treatments
14 nov. 2019 10h43 HE
|
UPMC Health Plan
Pittsburgh, Nov. 14, 2019 (GLOBE NEWSWIRE) -- UPMC Health Plan announced today that it has entered into a value-based agreement with Biogen for Tecfidera® (dimethyl fumarate) and Avonex® (interferon...
Biogen to Host Investor Webcasts from Clinical Trials on Alzheimer’s Disease (CTAD) Congress on December 5, 2019
04 nov. 2019 16h30 HE
|
Biogen Inc.
CAMBRIDGE, Mass., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) today announced it will host live webcasts of its oral presentation and a Q&A session related to its Alzheimer’s disease...
Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies
22 oct. 2019 06h30 HE
|
Biogen Inc.
New analysis of larger dataset showed that aducanumab reduced clinical decline in patients with early Alzheimer’s disease as measured by the pre-specified primary and secondary endpoints Based on...
Biogen Announces Leadership Update
01 oct. 2019 08h00 HE
|
Biogen Inc.
Dr. Alfred Sandrock is named Executive Vice President, Research and Development and continues as Chief Medical Officer Dr. Alphonse Galdes appointed Executive Vice President, Pharmaceutical...
Biogen Ranked #1 Biotechnology Company on Dow Jones Sustainability World Index
17 sept. 2019 07h30 HE
|
Biogen Inc.
CAMBRIDGE, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that it has been ranked the #1 biotechnology company on the Dow Jones Sustainability World Index (DJSI...
Biogen to Present New Safety and Efficacy Data on Biosimilars and Estimates 1.8 Billion Euros in Savings for the European Healthcare System in 2019
11 juin 2019 19h05 HE
|
Biogen Inc.
Data to be presented at the European Congress of Rheumatology (EULAR) 2019 highlight real-world evidence confirming the safety and efficacy of anti-TNF biosimilars and high adherence of patients to...
Biogen Completes Acquisition of Nightstar Therapeutics for Approximately $800 Million
07 juin 2019 05h41 HE
|
Biogen Inc.
CAMBRIDGE, Mass., June 07, 2019 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) today announced that it has completed its acquisition of Nightstar Therapeutics (NST; Nasdaq: NITE), a clinical-stage gene...